Skip to main content

Table 4 Spearman rank correlation of surgery ESR1 expression/pre-selected gene signature scores and percentage of 2-week change in Ki67/residual Ki67 level in HER2− tumours

From: Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients

Surgery gene signature scoresHER2− (n = 135)
Change in Ki67 (n = 121)Residual Ki67 (n = 124)
Signature nameReferenceRhop valueFDRRhop valueFDR
ESR1 − 0.193.42E−024.62E−02− 0.176.53E−026.53E−02
TP53-GSCoutant et al.− 0.477.43E−086.50E−07− 0.546.61E−113.57E−10
ERTarget27-GSVerhaeghCR2014TableS2− 0.263.96E−038.22E−03− 0.255.25E−037.46E−03
SET-GSSymmans et al.− 0.255.38E−031.04E−02− 0.37.82E−041.41E−03
ESR1.2-GSDesmedt et al.− 0.248.58E−031.32E−02− 0.272.52E−034.00E−03
ESR1.1-GSMackay et al.− 0.231.15E−021.63E−02− 0.291.34E−032.26E−03
ERGs-GSDunbier et al.− 0.093.56E−013.70E−01− 0.211.96E−022.21E−02
PIK3CA-GSLoi et al.− 0.055.53E−015.53E−01− 0.184.07E−024.23E−02
MacTh1-GSIglesia et al.0.0883.39E−013.66E−010.1992.64E−022.85E−02
Inflammatory-GSDunbier et al.0.1162.05E−012.31E−010.221.43E−021.68E−02
GDNF-GSMorandi et al.0.1162.04E−012.31E−010.2544.40E−036.60E−03
obesity-GSCreighton et al.0.1341.43E−011.76E−010.2397.61E−039.34E−03
Immune.2.STAT1-GSDesmedt et al.0.1588.26E−021.06E−010.2475.64E−037.61E−03
E2F3-GSBild et al.0.2378.79E−031.32E−020.247.38E−039.34E−03
IGF1-GSCreighton et al.0.248.06E−031.32E−020.3036.22E−041.20E−03
AKT/mTOR-GSMajumder et al.0.2495.83E−031.05E−020.3623.63E−057.54E−05
PTEN-GSSaale at al.0.2861.49E−033.35E−030.3926.68E−061.50E−05
PI3K-GSCreighton 20100.2911.21E−032.97E−030.4131.92E−064.71E−06
AURKA-GSDesmedt et al.0.323.53E−049.53E−040.4277.36E−071.99E−06
E2Factivation-GSMiller et al.0.3233.08E−049.24E−040.4325.39E−071.62E−06
E2FmotifCellCycleAssociated-GSMiller et al.0.4024.79E−061.62E−050.4541.22E−074.12E−07
Gene70-GSvan ‘t Veer et al.0.4318.22E−073.17E−060.5465.64E−113.57E−10
CIN70-GSCarter et al.0.4423.89E−071.75E−060.5292.79E−101.08E−09
E2F4activation-GSGuerrero-Zotano et al.0.4541.73E−079.34E−070.5351.51E−106.80E−10
GGI-GSSotiriou et al.0.4629.63E−086.50E−070.5714.52E−126.10E−11
JClinInvest2007RBloss-GSBosco et al.0.4911.12E−081.51E−070.5455.89E−113.57E−10
DiLeoRBloss-GSMalorni et al.0.5265.61E−101.51E−080.5841.08E−122.92E−11
  1. TP53-GS surgery score was the strongest inversely associated with the change in Ki67 and residual Ki67. The inverse correlation relates to high TP53-GS score being associated positively with TP53 wild-type status